The PE Recap is Back: Why 2026's Private Equity Medicine Revival Is Different—and More Dangerous—Than the Last One

The recapitalization wave physicians feared—and many hoped had passed—is back with full force in 2026. But this isn't the 2018–2021 boom reloaded. The buyer universe has structurally shifted, the academic evidence on post-exit harm is now damning and specific, and state legislatures are actively dismantling the legal scaffolding that made the first wave possible. Physicians sitting across the table from an exit offer today are operating in a fundamentally different risk environment than their colleagues who signed in 2019.

Global healthcare private equity shattered records in 2025, reaching an estimated $191 billion in deal value, surpassing even the 2021 peak. Sponsor-to-sponsor transactions—the recapitalizations that define PE-to-PE handoffs of physician platform companies—accounted for more than $120 billion of that total. The PPM exit logjam that froze deal activity in 2022 and 2023 is clearing.

Why PE Pulled Back After 2022—and What's Luring It Back Now

The 2022–2023 pullback had a simple cause: debt became expensive. Bain & Company's analysis documented how abrupt Federal Reserve rate hikes made leveraged buyout financing above $1 billion largely unavailable in the second half of 2022. Healthcare PE deal count fell roughly 30% from 2021 highs. Moody's found that 88% of the 34 North American healthcare companies it downgraded in late 2022 were PE-owned—a direct indictment of the debt-heavy capital structures that had characterized the first physician rollup wave.

The 2026 environment inverts nearly every one of those headwinds. Borrowing costs have eased. Equity markets are at record highs. The PPM platforms that survived the lean years have been forced by circumstance to actually build operational infrastructure—revenue cycle management, supply chain leverage, payer contracting—rather than relying purely on acquisition-driven EBITDA growth. Healthcare Business Today reports that the PPM sector's improved financial performance, combined with macro stability, is creating the conditions for a recapitalization super-cycle. For physicians who rolled equity in 2018–2020 and have been waiting on their "second bite of the apple," the math may finally be working. The danger is that it's also working for the next buyer, who will arrive with fresh leverage targets and a shorter exit horizon.

The New Buyer Class: Why Cardinal Health and Cencora Entering the Room Changes Everything

The most consequential structural change in the 2026 cycle isn't the return of traditional PE—it's the arrival of pharmaceutical distributors as direct physician group acquirers. This changes the strategic logic of the entire transaction from the ground up.

In November 2024, Cardinal Health announced a $2.8 billion acquisition of a 71% stake in GI Alliance, the country's largest gastroenterology MSO covering over 900 physicians across 345 locations in 20 states. This was immediately followed by the acquisition of Solaris Health, a urology MSO, for $1.9 billion. By mid-2025, Cardinal had launched "The Specialty Alliance"—a multi-specialty MSO platform supporting approximately 2,200 providers across 28 states.

Cencora matched this aggression. The company completed a $4.6 billion acquisition of Retina Consultants of America, securing approximately 85% of the nation's leading retina specialist MSO, and simultaneously accelerated its $5 billion investment in OneOncology.

The strategic logic here has nothing to do with traditional PE return profiles. Distributors are buying physician practices for buy-and-bill economics—the margin spread between the wholesale acquisition cost of specialty biologics and the reimbursement received when those drugs are administered in physician offices. Controlling the prescribing physician means controlling the drug utilization channel. For physicians in high-drug-volume specialties—gastroenterology, oncology, ophthalmology, urology, rheumatology—this means your acquirer's primary financial interest is in your prescription volume, not your clinical outcomes. That's a misalignment of incentives PE investors share in theory but distributors encode by design.

What the Harvard Research Actually Shows About Physician Turnover Post-Exit

The academic case against PE exits has moved from correlational anxiety to peer-reviewed specificity. Research from Harvard Kennedy School's Mossavar-Rahmani Center, published in early 2025 and covered in JAMA Health Forum, delivers the clearest finding yet: physicians in PE-exited practices were 16.5 percentage points more likely to leave their practice within two years of a secondary sale compared to matched peers in non-PE practices.

This matters because the recap cycle—PE Firm A sells to PE Firm B—is the dominant transaction structure in the 2026 market. Every sponsor-to-sponsor deal is a potential exit trigger for the physician workforce. The Harvard data, which analyzed CMS physician enrollment records from 2014–2020, found that departing physicians disproportionately migrated to large group practices (greater than 120 physicians), suggesting a consolidation flywheel: PE exits accelerate consolidation into mega-groups, which then become targets for the next acquisition wave.

Dermatology led in raw physician departures post-exit, followed by family medicine. As Health Affairs noted separately, PE-acquired primary care practices showed modest clinician growth offset by sharply elevated clinician exits. For a physician considering a deal today, the critical question is what happens to your panel when your PE sponsor decides to exit. The Harvard data suggests the answer is: disruption, consolidation, and likely higher costs for patients.

State Legislatures Are Closing the CPOM Loopholes

The corporate practice of medicine (CPOM) doctrine—which prohibits non-physician entities from owning medical practices in most states—was never actually a barrier to PE investment. The PC/MSO structure, where a physician-owned professional corporation (PC) handles clinical operations while a PE-controlled management services organization (MSO) handles everything else, became the standard workaround. In 2026, that workaround is under coordinated legislative assault.

California Governor Newsom signed SB 351 on October 6, 2025, effective January 1, 2026. The law directly prohibits PE firms and hedge funds from controlling clinical decisions of physicians and dentists—a structural challenge to standard MSO governance terms.

Oregon's SB 951 goes further, effectively banning arrangements inherent to the PC/MSO model and capping MSO operational control in ways that could render existing deal structures non-compliant.

Washington introduced 2SSB 5387 in January 2026, targeting the PC/MSO model explicitly by imposing new statutory requirements on PC ownership and governance. The Source on Healthcare Price & Competition is tracking an expanding number of similar bills nationally.

For physicians in these states, a deal structured on traditional MSO terms may not be legally defensible by the time the ink is dry on a secondary sale. For PE acquirers, deal structures now require state-specific legal analysis at the letter-of-intent stage, not at closing.

The Patient Cost Question: What Happens to Your Panel When the Recap Closes

The outcomes data on PE physician practice acquisitions is not ambiguous. The National Institute for Health Care Management documents that PE acquisition of physician practices is associated with increases in health care spending through higher prices and greater volume of profitable services. A comprehensive review found PE-owned practices performed nearly 20% fewer retinal detachment repairs—a time-sensitive procedure often reimbursed below cost—while increasing higher-margin, elective procedures.

For the physician weighing an exit offer, this is a professional ethics question as much as a financial one. Your rollover equity appreciates through mechanisms that include billing intensity increases, payer contract renegotiation, and service mix optimization. The Harvard post-exit turnover data compounds this: if your patients face practice disruption when the next PE exit occurs, the continuity-of-care harm is real and documentable.

What Physicians Should Demand in 2026 Deal Terms Before Signing Anything

The 2026 PE environment demands more sophisticated deal term negotiation than physicians exercised in the first cycle. A few non-negotiable structural protections:

Clinical autonomy provisions must be explicit and enforceable—not buried in MSO agreement boilerplate. Given California's SB 351 and analogous legislation, any governance term allowing the MSO to "direct" clinical protocols is now a legal liability in multiple jurisdictions.

CPOM-compliant deal architecture must be verified by healthcare regulatory counsel with specific knowledge of every state in which the practice operates. National platforms acquired into multi-state MSOs inherit the compliance obligations of every jurisdiction.

Rollover equity terms—including tag-along rights, drag-along protections, and equity anti-dilution provisions—must be negotiated at the letter-of-intent stage. Foley & Lardner's guidance is explicit: rollover equity structures that don't include robust exit rights leave physicians holding illiquid stakes with no enforcement mechanism when the next recap closes on unfavorable terms.

Physician turnover triggers—contractual protections that prevent post-closing compensation compression or non-compete enforcement against departing physicians—are a direct response to the Harvard turnover data. If the PE firm's exit depresses physician retention, that harm should be contractually bounded.

The record-setting 2025 deal volume and the emergence of distributor acquirers signal that the 2026 physician practice M&A market is more active, more complex, and more structurally risky than anything physicians navigated in the first PE wave. Physicians who treat exit offers the same way they treated them in 2019 will make 2019-vintage mistakes in a 2026-vintage regulatory and market environment. The academic evidence, the legislative trend, and the new buyer class all point in the same direction: the terms that matter most are the ones your attorney negotiates before you ever see a final purchase agreement.